Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 29A: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 4: | Line 4: | ||
|RefDocPart=Article 29A | |RefDocPart=Article 29A | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00049-Ser-Ver ++ TAG-00017-Spo-die ++ TAG-00057-Com-deR ++ TAG-00043-Goo-tek ++ TAG-00033-Pro-oto | ||
| | |RefModule=4 | ||
| | |RefUnit=4.1.4 | ||
}} | }} | ||
| Line 14: | Line 14: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 4 β Unit 4.1.4 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 30: | Line 33: | ||
| Β | | Β | ||
|- | |- | ||
! Tags | ! Tags | ||
| Β | | [[Glossary:TAG-00049-Ser-Ver|Serious breach]], [[Glossary:TAG-00017-Spo-die|Sponsor]], [[Glossary:TAG-00057-Com-deR|Competent authority]], [[Glossary:TAG-00043-Goo-tek|Good clinical practice]], [[Glossary:TAG-00033-Pro-oto|Protocol]] | ||
|- | |||
| Β | |||
|- | |||
| Β | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 4 β Unit 4.1.4 |
| Scope | HM |
| Document part | Article 29A |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Serious breach, Sponsor, Competent authority, Good clinical practice, Protocol |
| Comment | Sponsor obligation to notify licensing authority of serious breaches |
Content
29A. (1) The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of - (a) the conditions and principles of GCP in connection with that trial; or (b) the protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach. (2) For the purposes of this regulation, a βserious breachβ is a breach which is likely to effect to a significant degree β (a) the safety or physical or mental integrity of the subjects of the trial; or (b) the scientific value of the trial
